```
miR-1231   3'   cgUCGACAGGCGGGUCUGUg   5'
                  |   |   |   |   ||   :  | | | | | | | |
ELFN1-AS1  5'   gaATCCGGCC—TCCA[G]ACAc   3'


 miR-599   3'   caaacuauuuGACUGUGUUg   5'
                           |  | | | | | | | |
ELFN1-AS1  5'   atccggcctcCA[G]ACACAAt   3'
```

Supplementary Figure S1. Effect of the rs3735664 polymorphism on miR-1231 and miR-599 binding to *ELFN1-AS1*.

Supplementary Figure S3. Effect of different rs3735664 alleles on the binding of *ELFN1-AS1* to miR-1231.

Supplementary Figure S2. Effect of overexpression of *ELFN1-AS1* carrying different rs3735664 alleles on miR-1231 expression in CRC cells (A: Relative expression of ELFN1-AS1 in CRC cells; B: Relative expression of miR-1231 in CRC cells).

Supplementary Table S1. Demographic and clinicopathological characteristics of CRC patients and cancer-free individuals

Characteristics	CRC patients (n = 500)	Cancer-free individuals (n = 500)	P
Age (mean ± SD)	59.18 ± 7.46	59.70 ± 7.63	0.28
Gender, n (%)			
Female	226 (45.2)	217 (43.4)	0.57
Male	274 (54.8)	283 (56.6)	
TMN stages, n (%)			
I + II	248 (49.6)		
III + IV	252 (50.4)		

Supplementary Table S2. The primer sequences for qRT-PCR

Gene	Forward (5' to 3')	Reverse (5' to 3')
ELFN1-AS1	ACTCTCAGCCCCCACCTAGT	ATTCAACGGAAGAGGAAGCA
miR-599	GCCGAGGTTGTGTCAGTTT	CTCAACTGGTGTCGTGGAGT
miR-1231	CCTCAACTGAATTGCCGACTC	CTCAACTGGTGTCGTGGAGTC
GAPDH	CTCTGATTTGGTCGTATTGGGC	CCTGGAAGATGGTGATGGGATT
U6	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT